Media Centre
2023
Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model Nature Communications (November 2023)
2020
Developing new treatments in partnership for primary mitochondrial disease: What does industry need from academics, and what do academics need from industry? Journal of Inherited Metabolic Disease (November 2020)
Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity: Journal of the American Chemical Society (June 2020)
2017
Deubiquitylating enzymes and drug discovery: emerging opportunities: Nature Reviews Drug Discovery (2017)
2016
Activity Based Profiling of Deubiquitylating Enzymes and Inhibitors in Animal Tissues: Methods in Molecular Biology (Clifton, N.J.), 2016
Monitoring Target Engagement of Deubiquitylating Enzymes Using Activity Probes: Past, Present, and Future: Methods in Molecular Biology (Clifton, N.J.), 2016
Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors: Progress in Medicinal Chemistry, 2016
2015
USP4 Auto-Deubiquitylation Promotes Homologous Recombination: Molecular Cell, October 2015
2014
Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity: Nature Cell Biology, October 2014
2013
Deubiquitylating Enzymes and DNA Damage Response Pathways: Cell Biochemistry and Biophysics, May 2013
Regulation of DNA damage responses by ubiquitin and SUMO: Molecular Cell, March 2013
2009
The DNA Damage Response in Human Biology and Disease: Nature, October 2009
The Path to Progress: Niall Martin and Xavier Jacq (MISSION Therapeutics)
Get in touch
MISSION THERAPEUTICS
The Glenn Berge Building
Babraham Research Campus
Babraham
Cambridge
CB22 3FH
United Kingdom
T: +44 (0)1223 607 340
E: info@missiontherapeutics.com